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Renal Osteodistrophy: Histologic Evaluation After
Renal Transplantation
L. Martins, J. Queiro´s, A. Ferreira, A.C. Henriques, A.M. Sarmento, M.C. Pereira, and S. Guimara˜es
SUCCESSFUL RENAL transplantation (RT) is able tosolve most problems of uremic or dialyzed patients
(pt). However, renal osteodistrophy (RO) is often a long-
lasting problem, and bone disease can even worsen after
RT. In fact, significant changes in bone histology have been
seen up to 5 years after the procedure in more than 80% of
pt with a well-functioning kidney graft.1 Several factors,
including age,2,3 sex,4,5 underlying renal disease,3 time of
dialysis,6 type and severity of RO pre-RT,2,6 and also
immunosuppressive drugs4,7 may contribute to persistence
or worsening of RO.
Therefore, bone disorders still are a relevant morbidity
factor for RT, often difficult to handle. Dual-energy X-ray
absorptiometry (DEXA) is useful to measure bone mineral
density,5 but mineralized bone biopsy (BB) is the gold
standard to evaluate type and severity of RO. Only a few
have prospectively evaluated bone histology after RT. We
conducted a prospective study on renal transplant pt to
analyze the histologic evolution of RO after RT.
PATIENTS AND METHODS
Eight pt who completed the study were submitted to a first BB on
day 0 and a second BB 6 months after RT. The second BB was
performed after 500 mg dimethylchlortetracycline/day, double la-
beling (3 days on, 10 days off, 3 days on). Transiliac bone biopsies
using the trephine of Bordier-Meunier with an internal diameter of
8 mm were obtained in all pt. The bone specimens were fixed for 24
hours in methanol, dehydrated, and embedded in methylmetracry-
late. Undecalcified sections of 5-mm thickness were made using a
microtome (Model Leica RM 2155, Germany) equipped with a
tungsten carbide knife. Three nonconsecutive sections were stained
with Toluidine blue, acid phosphatase, and von Kossa. Two were
stained with a specific histochemical stain for detection of alumi-
num in bone (azurin solochrom) and one with a PERLS histochem-
ical stain for detection of iron in bone. Each bone section was read
twice by two different persons, without knowledge of clinical or
biochemical information on the pt. All sections were analyzed
quantitatively for static parameters of bone formation and bone
reabsorption. Histomorphometric measures were carried out using
a semiautomatic image analyzer (Q-Win, Leica, Germany) coupled
with a Leitz microscope. Approximately 40 different fields were
analyzed for the same bone biopsy. Normal bone histomorphomet-
ric values are from Vernejoul et al.8 The bone histomorphometric
parameters below, expressed according to the standardized nomen-
clature,9 were measured in trabecular bone.
All the pt were checked for intact parathyroid hormone (iPTH),
total alkaline phosphatase (tAP), serum calcium (Ca), and serum
phosphate (P) at time 0 and at 6 months. Serum creatinine was also
checked at 6 month. No patient received calcium or calcitriol
therapy after kidney transplantation. The immunosuppressive reg-
imen used was cyclosporine A (CsA) and prednisone in all pt; one
pt also had azathioprine; two pt also had antithymocytic globulin;
and another two also had micophenolate mofetil. Steroids were
used as three initial bolus of 500 mg methylprednisolone, followed
by 0.5 mg/kg per day of prednisone, tapered to 10 mg/d at the end
of the third month (our maintenance dose). None experienced
acute rejection episodes, so no further steroid bolus were used.
For the statistical analysis, paired t test and Wilcoxon test were
used.
RESULTS
Our study group was composed of five females and three
males, with a mean age of 50.4 6 9.8 years old (ranging
from 27 to 57). Their mean time on dialysis (all of them
were on hemodialysis) was 43.4 6 31.3 months (5 to 97
months). The underlying renal disease was unknown in two
pt, chronic glomerulonephritis in one pt, polycystic kidney
disease in three pt, and chronic interstitial nephritis in two
pt.
The mean and range of initial iPTH was 348.4 6 440.1
pg/mL (38.3 to 1288), and the final iPTH was 76.9 6 45.0
pg/mL (19 to 149), with the difference statistically signifi-
cant (P 5 .012). The mean initial tAP was 75.5 6 19.7 U/L,
and the final tAP was 95.8 6 32.8 U/L, although this
increment was not significant (P . .05). There was a
significant elevation on Ca during these 6 months (2.12 6
0.16 vs 2.36 6 0.13 mmol/L; P 5 .001) and a highly
significant decrease on P between the two measurements
(6.40 6 0.95 vs 3.13 6 0.24 mg/dL; P , .001). The mean
serum creatinine at month 6 was 1.2 6 0.3 mg/dL.
The histologic diagnosis from the initial and the final BB
is shown on Table 1. Between the two BB, we verified an
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increase in mineralized bone, an increase in osteoblastic
and osteoid surfaces, a decrease in osteoclastic surface and
osteoclast number, and a decrease in aluminum surface.
However, these changes were not statistically significant
(see Table 2).
DISCUSSION
RT normalizes phosphate urinary excretion and calcitriol
production,2 two of the most important deficiencies of the
uremic state implicated in RO. Also, aluminum overload is
efficiently removed by a functioning RT, although this can
take more than 1 year.2 Dialysis-related amyloidosis com-
plaints usually rapidly improve, although the cystic lesions
persist.2 However, severe pre-RT hyperparathyroidism
(HPTH), especially nodular hyperplasia, may not improve
after RT; indeed this may cause severe hypercalcemia and
graft dysfunction,10 making surgery necessary. Moreover,
steroids given for RT have a well-known effect on bone,
leading to bone mass loss4 and contributing to avascular
bone necrosis. CsA has also been associated with osteope-
nia7 and with a disabling bone pain syndrome.11 In addition,
adynamic bone disease has increased in the last years,3 and
although its significance is uncertain, it may contribute to
osteopenia observed after RT.
As easily understood from our results, some of the pt had
severe aluminum load pre-RT, which expectedly decreased
on second BB. However, high-turnover bone disease, al-
though not extremely severe, was the most frequent cause
of RO. These results are in accordance with the litera-
ture.2,3 Pre-RT severe osteoporosis was also identified in
two pt. Intact PTH and tAP decreased between the two
measurements, as previously described,12 and P showed the
expected lowering. On the contrary, Ca significantly in-
creased during this time interval, never reaching risky
levels. This increment may be long lasting and probably is
due to nonsolved HPTH.10 All the pt always had a good
graft function.
A significant loss in bone mass early after RT was made
evident by DEXA measurements, predominantly at the
lumbar spine. Up to 6.8%12 or even up to 10%2 reduction
on bone mass in the first 5 or 6 months has been seen.
Fortunately, this extremely high rate of bone loss progres-
sively falls: there are studies showing a trend toward
improvement after the sixth month5 and recovery at month
12,5 or normalization of bone mass only 2 years after RT.2
The less encouraging results show that the loss still exists
more than 8 years after RT, with a bone loss rate of 1.7%
per year.13
However, there is a lack of studies with histologic analysis
clarifying how the dynamic process of bone remodeling
really is functioning after RT. Some of the few published
works described a reduction in bone reabsorption, but with
low bone formation rate, as early as 6 months12 and even
several months later.14 Our study, with the handicap of only
eight pt enrolled, showed a trend toward improvement in
bone histology. Although the histologic changes between
Table 1. Bone Histology and Their Evolution Between the Two BB
Patient First BB Second BB
1 Moderate HPTH; extensive Al deposits; normal mineralization Mild HPTH; decrease in Al deposits; mineralization not
significantly compromised
2 Mild HPTH, severe osteoporosis, extensive Al deposits HPTH persists (predominant bone formation);
Al deposits diminished; normal mineralization
3 Severe HPTH, without Al deposition; normal mineralization Quite normal histology and normal bone volume
4 Moderate HPTH; significant Al deposits; normal
mineralization
Improved HPTH, evolving to low-turnover bone
disease; Al deposits decreased; osteoporosis
5 Quite normal bone histology; without significant Al deposition Quite normal histology
6 Severe HPTH (predominant bone formation); extensive Al
deposits; normal mineralization
Moderate HPTH; Al deposits decreased; mineralization
mildly compromised
7 HPTH on the past, evolving to adynamic bone disease;
extensive Al deposits; osteoporosis
Normal bone volume (osteoporosis improved);
Al deposits diminished; normal mineralization
8 Low-turnover bone disease; normal bone volume; significant
Al deposits
Mild HPTH; important decrease in Al deposits; normal
bone volume
HPTH 5 hyperparathyroidism; Al 5 aluminum.
Table 2. Bone Histomorphometry and Its Evolution Between the Two BB
First BB Second BB P value
Mineralized surface (%) 32.99 6 15.78 34.46 6 11.08 .780
Osteoid surface (%) 4.11 6 2.86 4.73 6 2.68 .676
Trabecular surface (%) 37.10 6 16.25 39.20 6 12.02 .699
Osteoblastic surface (%) 5.72 6 6.67 6.59 6 5.46 .769
Osteoclastic surface (%) 3.05 6 2.34 1.78 6 1.87 .176
Trabecular surface with aluminum (%) 39.83 6 35.38 30.98 6 28.73 .228
Number of osteoclasts/mm2 3.43 6 2.79 2.45 6 1.96 .302
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the two BB did not reach statistical significance, we ob-
served a trend toward improvement in bone formation and
mineralization, with reduction of bone reabsorption and
also important aluminum removal.
In conclusion, we can say that 6 months after RT there is
already a trend toward improvement in RO, which can
probably be clearly apparent a few months later, according
to DEXA results. A longer follow-up is needed to confirm
these results.
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